What adverse reactions happened during this study?
During the study, the participants did not take all of the study treatments. The
safety results in this part of the summary are for the participants who took the
indicated study treatments.
In Part 1:
X 3.4% of participants had an adverse reaction of headache. This was 1 out of
the 29 participants who took Treatment 2.
X 3.4% of participants had an adverse reaction of increased levels of ALT,
which is a protein made by the liver. This was 1 out of the 29 participants who
took Treatment 2.
In Part 2:
X 4.2% of participants had an adverse reaction of nausea. This was 1 out of the
24 participants who took Treatment 4.
How has this study helped patients and
researchers?
This study helped researchers learn more about how acalabrutinib acts in the
blood in healthy participants when taken in different ways.
Researchers look at the results of many studies to decide which treatments work
best and are safest. This summary shows only the main results from this one study.
Other studies may provide new information or different results.
Further clinical studies with acalabrutinib for the treatment of B-cell lymphoid
cancer are not currently planned.
11 | Clinical Study Results